SEARCH

SEARCH BY CITATION

References

  • 1
    Marnie TJ. Community-acquired pneumonia. State-of-the-art article. Clin Infect Dis 1994; 18: 50115.
  • 2
    Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 161824.
  • 3
    Ashby BL. Treatment of pneumonia: new strategies for changing pathogens. Clin Ther 1991; 13: 63750.
  • 4
    Venkatesan P, Macfarlane JT. Epidemiology, pathogenesis and prevention of pneumonia. Curr Opin Infect Dis 1991; 4: 1459.
  • 5
    Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993; 341: 51130.
  • 6
    Bartlett JC. Community-acquired pneumonia: current status. Infect Dis Clin Pract 1995; 4 (suppl 4): S22331.
  • 7
    Johnson JA. Pathogenesis of bacterial infections of the respiratory tract. Br J Biomed Sci 1995; 52: 15761.
  • 8
    Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993; 32(suppl A): 1727.
  • 9
    Carbon C, Leophonte P. Management of community-acquired pneumonia. J Antimicrob Chemother 1993; 32: 13.
  • 10
    Schutze GE, Kaplan SL, Jacobs RF. Resistant pneumococcus: a worldwide problem. Infection 1994; 22: 2337.
  • 11
    Yee YC, Thornsberry C. Penicillin-resistant Streptococcus pneumoniae on the rise in the United States: its effect on oral cephalosporins. Antimicrob Infect Dis Newslett 1994; 13: 4960.
  • 12
    Felmingham D, Grüneberg RN, The Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992–1993: The Alexander project. J Antimicrob Chemother 1996; 38(suppl A): 157.
  • 13
    Langtry HD, Lamb HM. Levofloxacin. Its uses in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487515.
  • 14
    Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (1-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36: 8606.
  • 15
    Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J Chemother 1996; 6: 8391.
  • 16
    Chien S-C, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 225660.
  • 17
    Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 10119.
  • 18
    Lee LJ, Sha X, Gotfried MH, Howard JR, Dix RK, Fish DN. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998; 18: 3541.
  • 19
    Nagai H, Yamasaki T, Matsuda M, Goto Y, Tasiro T, Nasu M. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993; 45(suppl 3): 259.
  • 20
    Nakamori Y, Miyashita Y, Nakatani I, Nakata K. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 41819.
  • 21
    DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997; 42: 20613.
  • 22
    File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 196572.
  • 23
    Norrby RS. Levofloxacin 2×500 mg iv (sequential therapy iv/oral) vs ceftriaxone 1×4.0 g iv in hospitalised patients with pneumonia. Scand J Infect Dis 1998; 30: 397404.
  • 24
    Shah P. Levofloxacin vs. cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis (AECB). J Antimicrob Chemother 1999; 43: 52939.
  • 25
    Cunha BA. Amoxycillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective. Clin Ther 1992; 14: 41825.
  • 26
    Legnani D. Role of antibiotics in treatment of community-acquired lower respiratory tract infections. Diagn Microbiol Infect Dis 1997; 27: 417.
  • 27
    Neu HC, Wilson APR, Grüneberg RN. Amoxyccillin/clavulanic acid: a review of its efficacy in 38 500 patients from 1979 to 1992. J Chemother 1993; 5: 6793.
  • 28
    Makuch K, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rev 1978; 62: 103740.
  • 29
    Harkins RD, Albrecht R. Design and analysis of clinical trials for anti-infective drug products. Drug Infect J 1990; 4: 21324.
  • 30
    Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications, 1987.
  • 31
    Barry AL. Antimicrobial agents for community-acquired respiratory tract infections. Infection 1995; 23(suppl 2): S59S64.
  • 32
    Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53: 81724.
  • 33
    Finch RG. The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995; 49(suppl 2): 14451.
  • 34
    Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53: 70025.
  • 35
    Portier H, May TH, the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community acquired pneumonia. J Antimicrob Chemother 1996; 37(suppl A): 8391.
  • 36
    Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin/clavulanic acid and erythromycin. Eur Respir J 1995; 8: 19992007.
  • 37
    Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 5201.
  • 38
    Carbon C, Léophonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother 1992; 36: 8339.